Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial

Annals of Oncology

Volumn 26, Issue 8, 2015, Pages 1710-1714

  Normanno, Nicola ^a   Rachiglio, A M ^a   Lambiase, M ^a   Martinelli, E ^b   Fenizia, F ^a   Esposito, C ^a   Roma, C ^a   Troiani, T ^b   Rizzi, D ^c   Tatangelo, F ^a   Botti, G ^a   Maiello, E ^d   Colucci, G ^c   Ciardiello, F ^b   Giuliani, F ^e   Simone, G ^e   Febbraro, A ^f   Tommaselli, E ^f   Cinieri, S ^g   Criscuolo, M ^g   Rinaldi, A ^h   Bordonaro, R ⁱ   Manusia, M ⁱ   Romito, S ^j   Bufo, P ^j   Carteni G ^k   Biglietto, M ^k   Nappi, O ^k   Montesarchio, E ^l   Micheli, P ^l   Nasti, G ^a   Chicchinelli, N ^a   Iannaccone, A ^a   Russo, A ^m   Cabibi, D ^m   Barone, C ⁿ   Rindi, G ⁿ   Tonini, G ^o   Onetti Muda, A ^o   Perrone, G ^o   Latiano, T ^d   Graziano, P ^d   Pisconti, S ^p   Sebastio, A ^p   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c GOIM Trial Office   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^f UO of Dermatology   (Italy)

^g Ospedale A Perrino   (Italy)

^h Presidio Ospedaliero Polo Occidentale   (Italy)

ⁱ GARIBALDI HOSPITAL   (Italy)

^j Ospedali Riuniti di Foggia   (Italy)

^k CARDARELLI HOSPITAL   (Italy)

^l MONALDI HOSPITAL   (Italy)

^m UNIVERSITY OF PALERMO   (Italy)

ⁿ FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^o Policlinico Universitario Gemelli di Roma ^*  (Italy)

^p Azienda Ospedaliera SS Annunziata   (Italy)

more..

Author keywords

Cetuximab; Colorectal cancer; Mutations; Next generation sequencing; Tumor heterogeneity

Indexed keywords

B RAF KINASE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PHOSPHATIDYLINOSITOL 3 KINASE; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; CAMPTOTHECIN; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; PIK3CA PROTEIN, HUMAN; PLATINUM COMPLEX; PROTEIN P21;

ALLELE; ARTICLE; BRAF GENE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER CELL LINE; DRUG RESPONSE; EXON; GENE FREQUENCY; GENE MUTATION; GENETIC HETEROGENEITY; HETEROZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; ONCOGENE N RAS; PIK3CA GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CARCINOMA; CLINICAL TRIAL; COLORECTAL NEOPLASMS; CONTROLLED STUDY; DRUG RESISTANCE; GENETICS; HIGH THROUGHPUT SEQUENCING; MULTICENTER STUDY; MUTATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SECONDARY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; CETUXIMAB; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE FREQUENCY; GTP PHOSPHOHYDROLASES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUCOVORIN; MEMBRANE PROTEINS; MUTATION; ORGANOPLATINUM COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); TREATMENT OUTCOME;

EID: 84940474576     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv176     Document Type: Article

References (20)

1. Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol 2014; 8: 1095-1111.
2. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013; 501: 338-345.
3. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034.
4. Heinemann V, von Weikersthal LF, Decker T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065-1075.
5. Normanno N, Tejpar S, Morgillo F et al. Implications for KRAS status and EGFRtargeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6: 519-527.
6. De Roock W, De Vriendt V, Normanno N et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12: 594-603.
7. De Luca A, Maiello MR, D'Alessio A et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012; 16(Suppl 2): S17-S27.
8. Network TCGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
9. Ciardiello F, Normanno N, Maiello E et al. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. Ann Oncol 2014; 25: 1756-1761.
10. Baldus SE, Schaefer KL, Engers R et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16: 790-799.
11. Losi L, Baisse B, Bouzourene H, Benhattar J. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 2005; 26: 916-922.
12. Kosmidou V, Oikonomou E, Vlassi M et al. Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications. Hum Mutat 2014; 35: 329-340.
13. Brannon AR, Vakiani E, Sylvester BE et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol 2014; 15: 454.
14. Santini D, Loupakis F, Vincenzi B et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 2008; 13: 1270-1275.
15. Sottoriva A, Kang H, Ma Z et al. A Big Bang model of human colorectal tumor growth. Nat Genet 2015; 47: 209-216.
16. Kopetz S, Desai J, Chan E et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 2010; 28: 3534.
17. Prahallad A, Sun C, Huang S et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-103.
18. Misale S, Di Nicolantonio F, Sartore-Bianchi A et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 2014; 4: 1269-1280.
19. Molinari F, Felicioni L, Buscarino M et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 2011; 17: 4901-4914.
20. Tougeron D, Lecomte T, Pages JC et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol 2013; 24: 1267-1273.